SEARCH WITHIN CONTENT
VOLUME 4 , ISSUE 3 ( July-September, 2020 ) > List of Articles
Aleena Gauri, Pramod Yadav, Pradeep K Prajapati
Keywords : Calcined copper, Coronavirus, COVID-19, SARS-CoV-2, Tamra Bhasma,Ayurveda
Citation Information : Gauri A, Yadav P, Prajapati PK. Possible Potential of Tamra Bhasma (Calcined Copper) in COVID-19 Management. J Res Ayurvedic Sci 2020; 4 (3):113-120.
License: CC BY-NC 4.0
Published Online: 21-12-2020
Copyright Statement: Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.
The complete genome sequence of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is 82% similar to SARS-CoV-1. The emerging coronaviruses, including SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV), have caused the recent pandemics of respiratory infectious diseases. Ayurveda makes use of metals and minerals in the form of Bhasma (calx) to treat various ailments. Ancient seers recommend Tamra Bhasma (calcined copper) and its formulations in various conditions including Kasa (cough), Shwasa (respiratory distress), Jwara (fever), Pinasa (chronic rhinitis/sinusitis), and as a Rasayana (rejuvenator). Rasa Bhasmas are claimed as biologically produced nanoparticles. The world is in need of an effective prophylactic and therapeutic agent for the prevention and control of coronavirus disease-2019 (COVID-19). This review article aims at suggesting Tamra Bhasma as a possible intervention in COVID-19. Calcined copper has been reported as sulfide and/or oxide of copper in major phases and some other trace elements. Safety aspects of calcined copper have been established previously. Copper was recognized in 2008 by the United States Environmental Protection Agency as the first metallic antimicrobial agent. Various studies show antimicrobial effect of copper, copper alloys, and various cupric and cuprous compounds against different viruses. Based on the evidences found in classical texts and preexisting antiviral studies, a lead can be made to employ calcined copper for its preclinical and clinical efficacy evaluation against the novel coronavirus SARS-CoV-2.